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The past five years have witnessed the discovery of the endoplasmic reticulum calcium (Ca2+) sensor STIM1 and the plasma 
membrane Ca2+ channel Orai1 as the bona fide molecular components of the store-operated Ca2+ entry (SOCE) and the Ca2+ 
release-activated Ca2+ current (ICRAC). It has been known for two decades that SOCE and ICRAC are required for lymphocyte ac-
tivation as evidenced by severe immunodeficient phenotypes in patients lacking ICRAC. In recent years however, studies have 
uncovered expression of STIM1 and Orai1 proteins in various tissues and described additional roles for these proteins in phys-
iological functions and pathophysiological conditions. Here, we will summarize novel findings pertaining to the role of STIM1 
and Orai1 in the vascular system and discuss their potential use as targets in the therapy of vascular disease. 
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Calcium (Ca2+) ions are universal second messengers and, 
unlike other second messengers, they are generally located 
outside the cells or stored in cell organelles such as the en-
doplasmic reticulum (ER). Resting cytoplasmic Ca2+ con-
centrations are maintained at 100–300 nmol L−1 [1–3], or-
ders of magnitude lower than the extracellular Ca2+ concen-
trations (1–2 mmol L−1). The ER lumen for instance usually 
maintains Ca2+ concentrations of around 500 μmol L−1 and 
is responsible for transient cytoplasmic Ca2+ increases upon 
extracellular stimulations. However, a sustained Ca2+ eleva-
tion requires Ca2+ entry from the extracellular space through 
Ca2+ channels located in the plasma membrane (PM). The 
Ca2+ entry happens concomitantly to the Ca2+ release from 
ER lumen and, in some cases, Ca2+ entry is triggered by 
Ca2+ release. The Ca2+ entry pathway that is specifically 
activated as a consequence of store emptying is called 
store-operated Ca2+ entry (SOCE) or capacitative Ca2+ entry 
[4–8], and the best characterized store-operated Ca2+ current 
is the calcium release-activated calcium current (ICRAC) [9]. 
Recent studies have identified the major protein compo-
nents of the SOCE pathway: the Ca2+ sensor protein STIM1 
[10,11] and the Ca2+ channel protein Orai1 [12,13]. 
Calcium release from ER lumen is achieved either ac-
tively through physiological agonist-mediated IP3 produc-
tion and subsequent activation of IP3 receptors or passively 
by pharmacological inhibition of the sarco-endoplasmic 
reticulum Ca2+-ATPase (SERCA) on the ER membrane by 
drugs such as thapsigargin. Store depletion causes the Ca2+ 
sensor STIM1 on the ER membrane to oligomerize and 
move to regions of close ER-PM junctions. Orai1 channels 
on the plasma membrane move to the same ER-PM junc-
tions and are activated by STIM1 oligomers through direct 
interaction of a minimal C-terminal 100 amino acid region 
of STIM1 to the C- and N-termini of Orai1 [14]. Ectopic 
expression of the minimal 100 amino acid region of STIM1 
which was termed SOAR (for STIM Orai Activating Region) 
or CAD (for CRAC activation Domain) [15,16] is sufficient 
to activate Orai1 channels and induce Ca2+ entry inde-
pendently of store depletion.  
There are other members of the STIM and Orai families 
encoded by separate genes: STIM2, Orai2 and Orai3. 
STIM2 appears to be involved in maintaining resting Ca2+ 
 Zhang W, Trebak M   Sci China Life Sci   August (2011) Vol.54 No.8 781 
concentrations. Orai2 and Orai3 are activated by STIM pro-
teins in a similar manner to Orai1 when co-expressed in 
HEK293 cells [14,17,18]. Orai3 has been shown to encode a 
native ICRAC-like conductance in breast cancer cells [19], 
and to contribute to heteromultimeric Orai3/Orai1 store-     
independent arachidonate-regulated Ca2+ channels [20]. The 
role of Orai2 in encoding native Ca2+ entry pathways re-
mains unclear. Ca2+ signaling and SOCE play an essential 
role in diverse cell functions and are involved in cellular 
dysfunctions, including those of the vascular system. 
1  Vascular smooth muscle cells and vascular 
proliferative diseases 
Vascular smooth muscle cells (VSMCs) are the most prom-
inent cell type in blood vessel wall and are responsible for 
the maintenance of vascular tone [21,22]. VSMCs disorders, 
usually manifested as a phenotype change, are involved in 
the pathogenesis of major vascular diseases such as athero-
sclerosis, hypertension and restenosis. Mechanical or in-
flammatory stimuli to the blood vessel site cause VSMCs to 
dedifferentiate from the fully mature quiescent contractile 
phenotype to an immature synthetic, proliferative and mi-
gratory phenotype. Synthetic VSMCs are mainly responsi-
ble for the narrowing of blood vessels in atherosclerosis 
[23,24] and restenosis [25] due to the proliferative/migra-     
tory VSMCs accumulation within the innermost layer of 
blood vessel wall. VSMC proliferation also occurs during 
vessel remodeling characteristic of development and pro-
gression of hypertension as increased presence of immature 
VSMC was found in the arterioles of hypertensive patients 
[26]. 
Ca2+ signaling modulates VSMC function, including 
phenotypic change, proliferation and migration. SOCE was 
found increased in synthetic VSMCs compared to the qui-
escent freshly isolated cells and this correlated with in-
creased protein expression of STIM1 and Orai1 [27,28]. 
Our lab has demonstrated STIM1 and Orai1 are essential 
components of SOCE and ICRAC in rat VSMCs [28]. The 
knockdown of STIM1 or Orai1 greatly reduced thapsigargin- 
or platelet derived growth factor (PDGF)-activated SOCE, as 
well as VSMC proliferation and migration [28,29]. STIM2, 
Orai2, Orai3, TRPC1, TRPC4 or TRPC6 knockdown did 
not show any effect on SOCE. Studies from other groups 
have also demonstrated that STIM1 is the major component 
of SOCE and plays an essential role in the proliferation of 
various types of VSMCs [30,31]. Using an in vivo model of 
VSMC proliferation and migration, STIM1 was found 
up-regulated in injured rat carotid arteries subjected to bal-
loon injury [29,32,33]. We reported that the protein expres-
sion of Orai1 is upregulated in media and neointima of ca-
rotid arteries from balloon-injured rats [29]. When an ade-
noviral vector encoding a short hairpin RNA (shRNA) 
against STIM1 was applied at the balloon-injured site to pre-
vent STIM1upregulation, neointima formation and the acti-
vation of transcription factor NFAT were prevented [32,33]. 
A recent report from our group demonstrated that prevention 
of Orai1 upregulation and ICRAC activation in the bal-
loon-injured carotid artery of rats using a lentiviral vector 
encoding shRNA inhibits NFAT nuclear translocation and 
activity, VSMC proliferation and neointima formation [34]. 
SOCE was also found increased in metabolic syndrome 
(MetS) swine coronary smooth muscle cells. MetS is a 
combination of medical disorders and MetS patients are at 
higher risk for coronary artery disease, stroke and type 2 
diabetes. The swine MetS model consists of 40 weeks on 
atherogenic diets and stent placement in coronary artery of 
male Ossabaw pigs [35,36]. The increase of SOCE in MetS 
smooth muscle cells was associated with increased STIM1, 
Orai1 and TRPC1 mRNA and protein levels [35]. However, 
the increase of SOCE and STIM1/TRPC1 protein overex-
pression were attenuated by subjecting the pigs to exercise 
training [35].  
Giachini et al. [37] have discovered a role for STIM1 and 
Orai1 in hypertensive rat aorta. Twenty-four weeks old 
stroke-prone spontaneously hypertensive rats (SHR) dis-
played higher systolic blood pressure, compared to Wistar-     
Kyoto (WKY) rats. Endothelium-denuded aortic rings from 
SHR displayed greater contractions than WKY rats during 
the Ca2+ store re-loading period following store depletion. 
Caffeine-induced SHR aortic contraction was greater than 
WKY rats’, and both contractions were dramatically sup-
pressed by CRAC channel blockers 2-aminophenyl borane 
(2-APB) and gadolinium (Gd3+). Application of Orai1 or 
STIM1 antibodies reduced the SR Ca2+ loading capacity and 
the transient aortic contractions of both SHR and WKY rats 
induced by caffeine and abolished the differences in con-
tractions between SHR and WKY rats. These authors 
showed higher protein and mRNA levels of STIM1 and 
Orai1 in SHR aortas. Immuno-fluorescence analysis con-
firmed the increased expression of STIM1 and Orai1 pro-
teins in SHR aortas [37]. Collectively, the data presented 
above supports a role for the SOCE pathway and STIM1/ 
Orai1 proteins in driving smooth muscle proliferation and 
migration and suggests the potential use of these proteins as 
targets for vascular occlusive diseases. 
2  Platelets and thrombosis 
Platelets are small anucleated cells derived from bone mar-
row megakaryocytes. They are circulating within the blood, 
being prepared to respond to any damage to the blood ves-
sels. The stimuli released from the injured site of blood 
vessel walls trigger platelets activation and aggregation, 
which cause blood coagulation to prevent bleeding (hemo-
stasis). However, when the platelets aggregation and blood 
coagulation are enhanced in response to severe damage and 
overwhelming stimuli, the blood clot formed inside the 
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vessel lumen obstructs the blood flow rather than heals the 
injury, and this process is a pathological one called throm-
bosis. Platelets activation is the major cause of thrombosis 
and is therefore the major target of antithrombotic therapy. 
Platelets activation and aggregation requires intracellular 
Ca2+ influx during the processes of their adhesion to the 
exposed subendothelium, aggregation and formation of 
clots in blood vessel lumen. Diverse agonists are involved 
in platelets activation through elevations of Ca2+ concentra-
tions, mainly through two different pathways [30]. Soluble 
agonists (thrombin, ADP and thromboxaneA2; TXA2) acti-
vate platelets through G protein-coupled receptors (P2Y, 
PAR, and TP respectively). G protein then leads to the acti-
vation of phospholipase Cβ (PLCβ) and IP3 production 
[38,39]. Adhesive ligands (von Willebrand factor; vWF, 
collagen, fibronection, etc.) activate platelet surface recep-
tors such as GPIb/V/IX, GPVI, and integrins, and trigger the 
production of IP3 by activation of phospholipase Cγ (PLCγ) 
[40]. Although both pathways can presumably activate 
SOCE by the production of IP3, the G protein pathway 
mainly triggers platelet-platelet interaction, while GPIb/     
V/XI and GPVI pathways mediate platelets aggregation 
through platelet-matrix adhesion. The cellular mechanisms 
of these processes remain largely unknown.  
Both STIM1 and Orai1 are found highly expressed in 
platelets, suggesting they might play an important role in 
platelet function. Bernhard Nieswandt group has generated 
three types of SOCE-impaired mice line: STIM1sax/sax (an 
activating STIM1 EF hand D84G mutant), STIM1−/−, and 
Orai1−/− [41–43]. The STIM1sax/sax homozygous mice em-
bryos had severe hemorrhage and only a few of them sur-
vived until E13-E14. Due to the high lethality and low sur-
vival of homozygous animals (1 out of 72 offspring), most 
of the work was done in the STIM1sax/+ heterozygous mice 
in which the impairment of SOCE and platelets function 
was also observed. Platelets from STIM1sax/+ mice were 
pre-activated, displayed elevated basal Ca2+ concentrations 
and a short life span. Ca2+ store release evoked by thapsgar-
gin (TG) was reduced by 60% in the platelets from these 
heterozygous animals and the subsequent Ca2+ influx (in the 
presence of 2 mmol L−1 extracellular Ca2+) was reduced by 
70% compared with wild type. One important mechanism 
was discovered when the authors compared the Ca2+ influx 
in response to agonists in STIM1sax/+ and wild type platelets. 
They found that Ca2+ influx in STIM1 mutant platelets was 
reduced only upon stimulation with collagen receptor-spe-     
cific agonists (such as collagen related peptide; CRP and 
rhodocytin; RC) [42]. Those receptors are associated with the 
immunoreceptor tyrosine-based activating motif (ITAM) and 
trigger Ca2+ influx through activation of the PLCγ pathway, 
reminiscent of T cell receptor activation [44]. In contrast, 
when G protein coupled agonists such as thrombin and ADP 
were applied, levels of Ca2+ rise were similar in both mutant 
and wild type platelets [42]. The STIM1sax/+ mice blood also 
showed less adhesion to the collagen surface than wild type. 
Tail bleeding times were significantly prolonged in 
STIM1sax/+ mice. One specific injury model was used, in 
which the thrombus formation is mainly driven by thrombin, 
and the formation times of occlusion were similar in 
STIM1sax/+ mice and wild type mice [42]. 
In the STIM1−/− mice platelets, Ca2+ influx evoked by ei-
ther CRP or by the G protein-coupled agonists (ADP, 
thrombin and TXA2 analogue U46619) was suppressed. 
However, in a manner similar to STIM1sax/+ mice, platelets 
aggregation was only diminished in STIM1−/− blood when 
triggered by collagen-related agonists, and did not change in 
STIM1−/− blood when triggered by G protein-coupled ago-
nists, compared to wild type. The experiments of three-di-     
mensional growth of thrombi on collagen-coated surface 
showed that STIM1−/− platelets formed less thrombus than 
the wild type did. Surface area covered by mutant platelets 
was reduced by ~42%, and the total volume of thrombus 
formed by mutant platelets was reduced by ~81%. In vivo 
experiments showed a mild prolongation of tail bleeding 
time, a significant delay in vessel occlusion time and a high 
resistance to ischemic brain infarction in STIM1−/− mice 
[43].  
Orai1 was found to be the predominant member of the 
Orai family in both human and mice platelets. Because the 
Orai1 knockout mice showed very high mortality, Braun et 
al. [41] transplanted Orai1−/− bone marrow to irradiated 
wild-type mice and generated platelets Orai1−/− chimeric mice. 
Thapsigargin-evoked SOCE was dramatically suppressed in 
platelets, indicating that Orai1 is the essential component of 
SOCE in these cells. Very similar to STIM1−/− platelets, the 
Ca2+ influx of Orai1−/− platelets was inhibited in response to 
CRP, ADP and thrombin. However, the Orai1−/− platelets 
aggregation in response to G protein-coupled agonists (ADP 
and thrombin) was comparable to wild type, but was dimin-
ished in response to low concentration of collagen or CRP. 
Intravenous injection of collagen/epinephrine caused death 
of wild type mice within 20 min by pulmonary thrombo-
embolism, whereas most Orai1−/− mice (6 out of 7) survived 
[41]. In an arterial thrombosis model, whereas all the wild 
type mice got complete occlusion, 4 out of 10 Orai1- 
knockout mice had maintained blood flow. In a FeCl3-in-     
duced arterioles injury model, where the thrombus for-
mation mainly depends on thrombin, 14 out of 15 Orai1−/− 
mice had occlusive thrombi and the process was similar to 
wild type mice. Similar to the STIM1−/− mice, the Orai1−/− 
mice showed high resistance to ischemic brain infarction 
[41]. Around the same time, Stefan Feske’s group generated 
chimeric mice expressing Orai1R93W exclusively in blood 
cells [45]; Orai1R93W is the mutation of Orai1 found in se-
vere combined immunodeficient patients (SCID) character-
ized by abrogated SOCE and ICRAC [46]. Ca
2+ entry was 
impaired when Orai1R93W platelets were stimulated by either 
thapsigargin or agonists (PAR4p or convulxin to active 
PAR4 or GPVI respectively). However, platelet aggregation 
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and thrombus formation was not apparently affected [45]. 
Since mice harboring Orai1R93W mutation are equivalent to 
human SCID patients with Orai1R91W mutation and these 
patients did not show any obvious bleeding or clotting is-
sues, these results are consistent with the clinical observa-
tions. However, these authors found that exposure of phos-
phatidylserine (PS) on cell surface of Orai1R91W platelets 
was reduced by 80% [45]. The cell surface exposure of PS 
is required for platelet procoagulant activity and is triggered 
by cytosolic Ca2+ elevation. These results were confirmed 
by the Nieswandt group where PS exposure and thrombus 
generation was suppressed in STIM1−/− and Orai1−/− mice 
when triggered through the GPVI pathway (using convulxin 
as an agonist) but not through thrombin stimulation; STIM2 
did not show any apparent role in these processes [47].  
To summarize, STIM1 and Orai1 are the major compo-
nents of SOCE in platelets and dominate the Ca2+ Entry 
through GPIb-GPVI-ITAM signaling pathway. Deficiency 
of STIM1 or Orai1 reduced thrombosis formation in arteries 
(subjected to high shear flow conditions) when triggered 
mainly by collagen (through GPVI/ PLCγ pathway). In con-
trast, STIM1 and Orai1 did not show any evident effect in 
hemostasis at the wound bleeding site, where abundant tis-
sue factors are involved and thrombus formation is triggered 
mainly by thrombin or other tissue factors acting through G 
protein coupled receptors involving the activation of the 
PLCβ pathway. 
3  Endothelial cells and angiogenesis 
Endothelial cells line the inner side of blood vessels and 
help maintain vascular tone through production of nitric 
oxide and act as a barrier between the circulating blood and 
the surrounding tissue. Endothelial dysfunction is involved 
in various cardiovascular diseases.  
Endothelial cells have been known for a while to express 
the SOCE pathway [48,49] and the elevation of Ca2+ con-
centration in cytoplasm plays an important role in a variety 
of endothelial cell functions, such as barrier function, motil-
ity, proliferation, migration and angiogenesis [50–54]. 
Work in our lab showed that endothelial cells from different 
vascular beds, human umbilical vein endothelial cells 
(HUVEC) and human pulmonary artery endothelial cells 
(HPAEC) express STIM and Orai proteins and display 
SOCE and ICRAC that are encoded by STIM1 and Orai1 [55]. 
Interestingly, endothelial agonists such as vascular endothe-
lial growth factor (VEGF) or thrombin regulate intracellular 
calcium entry through STIM1/Orai1-mediated SOCE [55]. 
STIM1/Orai1-mediated SOCE plays an essential role in 
HUVEC proliferation; STIM1 or Orai1 knockdown using 
silencing RNA (siRNA) leads to cell cycle arrest at S and 
G2/M phases of the cell cycle [55]. Orai1 and SOCE are 
also functional in HUVEC angiogenesis [56]. Knockdown 
of Orai1 or STIM1 by siRNA suppressed VEGF-evoked 
Ca2+ entry and inhibited HUVEC migration through 8-μm 
pores. Orai1 was pivotal for tube formation of HUVEC in 
Matrigel, suggesting Orai1 as a potential target in angio-
genesis. A CRAC channel inhibitor, S66, showed similar 
effect on tube formation and also inhibited vessel growth in 
an in vivo model of angiogenesis [56]. SOCE was also 
found expressed in human Endothelial Progenitor Cells 
(EPC) [57], including those harvested from peripheral blood 
(PB-EPC) and umbilical cord blood (UCB-EPC). Orai1 and 
STIM1 were more abundant in both types of EPCs, and 
were proposed as the major components of SOCE. Knock-
down of STIM1 attenuated hepatocyte growth factor 
(HGF)-induced SOCE and proliferation in EPC [58].  
4  Cardiac function and hypertrophy 
Ohba et al. [59] demonstrated that rat cardiomyocytes ex-
pressed STIM1 and that knockdown of STIM1 inhibited 
Ca2+ entry in response to thapsigargin and endothelin-1. 
Importantly, STIM1 knockdown inhibited endothelin1-me-     
diated nuclear factor for activated T-cells (NFAT) activa-
tion and prevented the increase of cardiac fetal genes in-
duced by hypertrophic stimuli such as endothelin-1, phe-
nyl-epinephrine [59]. Voelkers et al. [60] demonstrated that 
STIM1 and Orai1 proteins are required for thapsigar-
gin-mediated SOCE and Ca2+ transients in neonatal cardio-
myocytes. These authors also showed that knockdown of 
Orai1 caused a significant decrease in cardiac fetal genes 
expression and size of neonatal cardiomyocytes and a re-
duction in ERK1/2 phosphorylation and calcineurin activa-
tion under resting conditions and hypertrophic stimulation 
with phenylepinephrine [60]. However, STIM1 knockdown 
caused a significant decrease in cell size only in response to 
hypertrophic stimulation with phenylephrine, but had no 
effect under resting conditions. These data support a role for 
STIM1 and Orai1 in hypertrophic cardiac remodeling [60].  
5  Conclusion 
STIM1 and Orai1 have recently emerged as mediators for 
SOCE in several cell types including those of the cardio-
vascular system. The contribution of STIM1 and Orai1 to 
cardiovascular diseases is also beginning to emerge. As of 
this writing, there is no indication for a role of Orai2 or 
Orai3 in the cardiovascular system but future research is 
likely to unravel novel roles for these isoforms. Orai 
isoforms are known to heteromultimerize, suggesting means 
to enhance the diversity of calcium signals induced by spe-
cific agonists to control specific physiological functions. 
We look forward to future work to unravel additional roles, 
oligomerization patterns and regulation mechanisms for 
native STIM and Orai proteins in different cells of the car-
diovascular system. Deciphering subtle differences of Orai 
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channel organization and regulation between different cell 
types might make selective targeting of these molecules in 
treatment of cardiovascular diseases a reality. 
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